Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dusquetide for Aphthous Ulcers in Behcet's Disease
NCT06386744Phase 2Completed
- Sponsor
- Soligenix
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of dusquetide in Behcet's disease (BD), sponsored by Soligenix. Started Nov 2024; status: completed.
02
Drugs
dusquetide
03
Conditions
Behcet's disease (BD)
Beyond the preview
Go deeper on NCT06386744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06386744.